| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Mitomycin-C | CTRPv2 | pan-cancer | AAC | 0.087 | 0.008 |
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | 0.09 | 0.008 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.085 | 0.009 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | 0.093 | 0.01 |
| mRNA | BRD-K07442505 | CTRPv2 | pan-cancer | AAC | 0.094 | 0.01 |
| mRNA | MPS-1-IN-1 | GDSC1000 | pan-cancer | AAC | 0.078 | 0.01 |
| mRNA | YK 4-279 | CTRPv2 | pan-cancer | AAC | 0.08 | 0.01 |
| mRNA | Bleomycin | CTRPv2 | pan-cancer | AAC | 0.093 | 0.01 |
| mRNA | 5-FU | CTRPv2 | pan-cancer | AAC | 0.084 | 0.01 |
| mRNA | PF-184 | CTRPv2 | pan-cancer | AAC | 0.082 | 0.01 |